20200212 FOI ref 668-1920

Adalimumab FOI request

Dear those concerned,

Please see the below a Freedom of Information request:

Question 1

	Rheumatology	Dermatology	Gastroenterology
Is the branded biosimilar	Not applicable at	Yes as long as it is	Yes as long as it is
AMGEVITA listed on your	UHNM	used within NICE	used within NICE
formulary?		guidance	guidance

Question 2

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the	Rheumatology	Dermatology	Gastroenterology
adalimumab therapy pathway*			
AMGEVITA first/second-line	Not applicable at	0	13
HUMIRA first/second-line	UHNM	33	231
HYRIMOZ		81	258
IMRALDI		0	0

^{*}How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

Question 3

Please complete the table below:

	Department					
Question	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic	Rheumatoid	Ankylosi	Crohn's	Ulcerative
		arthritis	arthritis	ng	disease	colitis
				spondyl		
				itis		
Are any local	Yes	Not applicable at UHNM		NO (Local	NO (Local	
guidelines followed					Guidance is	Guidance is
that recommend					in line with	in line with
earlier use of anti-					NICE	NICE
TNF biologics/ biosimilars in the					Guidance)	Guidance)
treatment						
pathway?						

Are there occasions	No	No	No
where patients can			
receive			
adalimumab			
outside of			
NICE/SMC/AWMSG			
/National criteria?			

Question 4

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?

Contractual agreement	Yes/No		
Block contracts			
Fixed price on a patient-by-patient basis	Yes – national reference price used as NHS		
	circular ref:000434		

Please let us know if you require any further information to process this request or if this request needs to be directed elsewhere. Many thanks.

Kind regards,